China
Africa
Explore chapters and articles related to this topic
Mood Disorders
Published in Vincenzo Berghella, Maternal-Fetal Evidence Based Guidelines, 2022
Madeleine A. Becker, Tal E. Weinberger, Leigh J. Ocker
There are no screening instruments specifically designed to detect mood episodes in patients with bipolar disorder, before or after delivery. Commonly used screening instruments, such as the EPDS, have not been validated in postpartum women with BAD [32]. Of all the screening instruments for BAD used in the general population, the Mood Disorders Questionnaire (MDQ) has been most widely studied, both in psychiatric settings as well as primary care and community settings.
Special Issues in Patients with Comorbid Psychiatric and Chemical Dependency Disorders
Published in John Brick, Handbook of the Medical Consequences of Alcohol and Drug Abuse, 2012
Mark C. Wallen, William J. Lorman
Unfortunately, most screening and assessment instruments are proprietary and the clinician must pay a fee to use the tool. However, there are many public domain instruments available. In addition to the Hamilton scales identified in the previous text, the Internet can be a source of a variety of instruments, such as the Montgomery-Asberg Depression Rating Scale (MADRS); Inventory of Depressive Symptomatology (IDS-C); Young Mania Rating Scale (YMRS); Clinical Global Impression–Bipolar (CGI-BP); and Mood Disorder Questionnaire (MDQ). The name of the instrument generally defines the syndrome being evaluated.
Medical Management of Obesity Associated with Mood Disorders
Published in Susan L. McElroy, David B. Allison, George A. Bray, Obesity and Mental Disorders, 2006
Susan L. McElroy, Renu Kotwal, Paul E. Keck
A complete assessment for a lifetime mood disorder includes a psychiatric and medical history, family and social history, and mental status exam with a focus on current and lifetime mood, psychotic, anxiety, substance use, eating, and impulse control disorder signs and symptoms. Because bipolar disorder frequently presents as depression, comorbid Axis I disorders, Axis II personality disorders, behavioral dysregulation (including hypersexuality and antisocial behavior), or general medical disorders (e.g., migraine and other types of pain), it is important to carefully evaluate for a history of hypomania or mania, including subthreshold hypomanic symptoms, in patients with these presentations (370). Because patients often have difficulty identifying or recognizing hypomania, the use of screening instruments, such as the Mood Disorder Questionnaire (MDQ) or the Hypomania Symptom Checklist, and structured clinical interviews, such as the Structured Clinical Interview for DSM-IV (SCID), in combination with consultation of a significant other (with the patient’s permission), will improve the identification of bipolarity, particularly “soft” or “occult” forms (371–373).
Total healthcare cost savings through improved bipolar I disorder identification using the Rapid Mood Screener in patients diagnosed with major depressive disorder
Published in Current Medical Research and Opinion, 2023
Roger S. McIntyre, Lisa Bloudek, Jack Y. Timmons, Patrick Gillard, Amanda Harrington
The model was structured based on a prior analysis of screening in BP-I using the Mood Disorder Questionnaire (MDQ)18. Among all patients, there was an underlying true prevalence of BP-I misdiagnosis and correctly diagnosed MDD, and the population was apportioned into those who were screened for BP-I and those who were not (Figure 1). In the screening branch of the model, patients completed the 6-item RMS. For all patients who screened positive on the RMS (i.e. true and false positives), it was assumed that each had a follow-up visit with a specialist to confirm the screening result, or identify a false positive and confirm an MDD diagnosis. Patients who are correctly diagnosed at any point were assumed to remain in that health state throughout the remainder of the model time horizon.
The Rapid Mood Screener (RMS): a novel and pragmatic screener for bipolar I disorder
Published in Current Medical Research and Opinion, 2021
Roger S. McIntyre, Mehul D. Patel, Prakash S. Masand, Amanda Harrington, Patrick Gillard, Susan L. McElroy, Kate Sullivan, C. Brendan Montano, T. Michelle Brown, Lauren Nelson, Rakesh Jain
For participants who met inclusion criteria at screening, the self-reported diagnosis was confirmed by a Mini-International Neuropsychiatric Interview (MINI) structured clinical interview [19]. Two MINI modules were administered for diagnostic purposes (depressive disorder [Module A] and bipolar disorder [Module C]), and 2 modules were administered to rule out other diagnoses (any psychotic disorder [Module K] and medical, organic, or drug causes [Module O]). A MINI question related to repeated thoughts about death and suicide was not administered to minimize emotional risk to study participants and preempt discussion of the topic given the nonclinical study setting. The items of the draft bipolar I disorder screening tool were administered to participants; more clinical information was elicited via self-reported responses to additional questions that provided numeric variations (e.g. number of episodes, age of onset, prior number of antidepressants) and content permutations (e.g. comorbidities, family mental health history) for some draft items. Additional study measures included the 15-item Mood Disorder Questionnaire (MDQ) to screen for bipolar disorder [20] and the 20-item Center for Epidemiologic Studies Depression Scale (CES-D), used to assess the severity of depressive symptoms over the prior week [21].
Improving Knowledge and Increasing Use of a Screening Tool in an Outpatient Psychiatric Clinic
Published in Issues in Mental Health Nursing, 2020
Mary Kiesewetter, Marsha Snyder, Suzanna Kitten
Carvalho et al. (2015) identified that self-report screening tools can be time and cost effective and help shorten the gap between experiencing symptoms and receiving an accurate diagnosis and treatment. Overall, screening instruments for BD have high specificity, meaning they are effective to screen out true negatives, which can provide valuable time for the busy practitioner (Carvalhoe et al., 2015). Carta and Angst (2016) provided expert opinion on the use of screening tools for early detection of BD. They identified that assessment tools, specifically the Mood Disorder Questionnaire (MDQ), can produce false positives, confusing symptoms with other mental illnesses such as Borderline Personality Disorder (Carta & Angst, 2016). However, they argue that screening tools have similar if not identical rates of false negatives as a diagnostic interview (Carta & Angst, 2016). While the rate of persons with BD is likely underestimated, a small percentage (1%) of persons with true Major Depressive Disorder will develop BD, lending to the idea of periodic application of diagnostic assessment tools (Carta & Angst, 2016). Likewise, Graham and Parker (2015) reviewed and gave their expert opinion on current principal screening measures for BD, and advised that BD screening tools can play an important role in early detection of BD but should be used in the first stage of screening, followed by a diagnostic interview.